We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Adma Biologics (ADMA) Sees a More Significant Dip Than Broader Market: Some Facts to Know
Read MoreHide Full Article
Adma Biologics (ADMA - Free Report) closed the most recent trading day at $17.70, moving -1.28% from the previous trading session. This move lagged the S&P 500's daily loss of 0.19%. On the other hand, the Dow registered a loss of 0.8%, and the technology-centric Nasdaq decreased by 0.1%.
Shares of the infectious disease drug developer witnessed a loss of 9.12% over the previous month, trailing the performance of the Medical sector with its gain of 0.48%, and the S&P 500's gain of 2.26%.
Investors will be eagerly watching for the performance of Adma Biologics in its upcoming earnings disclosure.
ADMA's full-year Zacks Consensus Estimates are calling for earnings of $0.57 per share and revenue of $0 million. These results would represent year-over-year changes of +16.33% and 0%, respectively.
Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Adma Biologics. Recent revisions tend to reflect the latest near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has remained steady. Adma Biologics presently features a Zacks Rank of #3 (Hold).
Looking at valuation, Adma Biologics is presently trading at a Forward P/E ratio of 21.87. This indicates a premium in contrast to its industry's Forward P/E of 20.92.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 99, putting it in the top 41% of all 250+ industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Adma Biologics (ADMA) Sees a More Significant Dip Than Broader Market: Some Facts to Know
Adma Biologics (ADMA - Free Report) closed the most recent trading day at $17.70, moving -1.28% from the previous trading session. This move lagged the S&P 500's daily loss of 0.19%. On the other hand, the Dow registered a loss of 0.8%, and the technology-centric Nasdaq decreased by 0.1%.
Shares of the infectious disease drug developer witnessed a loss of 9.12% over the previous month, trailing the performance of the Medical sector with its gain of 0.48%, and the S&P 500's gain of 2.26%.
Investors will be eagerly watching for the performance of Adma Biologics in its upcoming earnings disclosure.
ADMA's full-year Zacks Consensus Estimates are calling for earnings of $0.57 per share and revenue of $0 million. These results would represent year-over-year changes of +16.33% and 0%, respectively.
Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Adma Biologics. Recent revisions tend to reflect the latest near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has remained steady. Adma Biologics presently features a Zacks Rank of #3 (Hold).
Looking at valuation, Adma Biologics is presently trading at a Forward P/E ratio of 21.87. This indicates a premium in contrast to its industry's Forward P/E of 20.92.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 99, putting it in the top 41% of all 250+ industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.